In developed countries, women attend follow-up after treatment for cervical cancer to detect recurrence. The aim of this study was to describe the Danish population of women with early-stage cervical cancer at risk for recurrence and death due to recurrence. METHODS: Data were extracted from 3 nationwide databases to find women diagnosed with stage 1A1 to 1B1 cervical cancer in [2005][2006][2007][2008][2009][2010][2011][2012][2013]. Recurrences were determined from data on oncological or surgical treatment more than 3 months after the initial diagnosis and were cross-checked with patient journals. RESULTS: In all, 1523 patients were diagnosed with stage 1A1 to 1B1 cervical cancer. Eighty women experienced recurrences: 8 at International Federation of Gynecology and Obstetrics (FIGO) stage 1A1, 0 at FIGO stage 1A2, and 72 at FIGO stage 1B1. The 5-year recurrence rate was 6.4%; 67.5% of the women had symptomatic recurrences, and 28.8% had asymptomatic recurrences. At significantly greater risk for recurrence were women at stage 1B1, regardless of their lymph node (LN) status at diagnosis (hazard ratio with a positive LN, 5.10; 95% confidence interval [CI], 1.65-15.76; P 5.0047; hazard ratio with a negative LN, 3.14; 95% CI, 1.25-7.93; P 5.0153; hazard ratio with LN data missing, 6.33; 95% CI, 1.80-22.26; P 5.004), women older than 50 years (hazard ratio, 1.81; 95% CI, 1.12-2.94; P 5.0158), and women with lymphatic and lymphovascular space invasion (LVSI; hazard ratio, 1.92; 95% CI, 1.11-3.30; P 5.0188). In a multivariate analysis, significantly inferior survival was found after recurrence for patients with lymphatic LVSI (hazard ratio, 2.23; 95% CI, 1.04-4.80; P 5.0401), a symptomatic diagnosis of recurrence (hazard ratio, 2.52; 95% CI, 1.08-5.90; P 5.0332), and multiple sites of recurrence (hazard ratio, 2.72; 95% CI, 1.32-5.61; P 5.0066). CONCLUSIONS: This study has identified a group of women at FIGO stage 1A1 in no need of specialized, hospital-based follow-up. Many of the recurrences at FIGO stage 1B1 are asymptomatic, and this may show a need for follow-up in this group. Further prospective investigation is needed. Cancer 2018;124:943-51.
INTRODUCTION
Cervical cancer is accountable for approximately 528,000 new cases per year worldwide and approximately 266,000 deaths per year.
1,2 Screening, diagnosis, and treatment have all improved the outcomes for women with cervical cancer over the past decades, and this has resulted in an increased prevalence in industrialized countries. 3 This puts strain on health care systems worldwide and has an impact on current practice, notably with respect to follow-up because the majority of these patients are without disease and yet are taking up an abundance of resources within hospitals. 4, 5 Patients diagnosed with cervical cancer are treated according to the International Federation of Gynecology and Obstetrics (FIGO) guidelines and are allocated to follow-up regardless of their initial FIGO classification. 6 Patients are clinically staged before treatment and are not upstaged if there are unexpected perioperative or postoperative findings such as metastatic lymph nodes (LNs). Danish patients at FIGO stages 1A1 to 2A with tumor sizes 4 cm are considered lowrisk patients with respect to the risk of recurrence and death and undergo primary surgical treatment. In Denmark, patients at FIGO stages 1B1 to 2A are offered adjuvant oncological treatment with radiotherapy and concomitant chemotherapy if any of the following risk factors are present: positive LNs; parametrial invasion; tumor size > 3 cm and depth of stromal invasion (DSI) > 2/3; tumor size > 2 cm and DSI > 1/3 and lymphovascular space invasion (LVSI); and nonradical resection. 7 Patients with a higher FIGO stage at the initial diagnosis undergo radiotherapy and concomitant chemotherapy and are categorized as high-risk patients. However, this division into low and high risk seems irrelevant to patients in the low-risk group who experience recurrence and a subsequent risk of cancer death. To the study group's knowledge, there are no other methods (eg, clinical, demographic, or biological) with which to classify patients according to the risk of recurrence and hence to handle patients in the follow-up period.
An important aim of follow-up is to diagnose early recurrence under the assumption that an early pelvic recurrence results in prolonged survival because of the possibility of salvage treatment, either by surgery or by radiotherapy. 8 For this reason, a smear has been a part of routine follow-up visits for patients treated with hysterectomy at the initial diagnosis. Systematic evidence-based literature to support this assumption is lacking, and this has resulted in large variations in the management of follow-up regimens across Europe. 3, [9] [10] [11] Previous studies inform us that 10% to 20% of patients with low-risk disease will experience relapse, 4% to 5% of whom will have a pelvic recurrence and approximately 1% to 2% of whom can be salvaged. 1, 8, 12 Hence, it is of grave importance to describe and classify the patients at risk to optimize the follow-up program. One study even suggested that routine follow-up delays the detection of recurrences because symptomatic women postpone seeking medical advice until the next planned visit. 13 To accommodate known recurrence patterns, the Danish health authorities and experts agreed in 2015 on more individualized follow-up and aimed to augment the focus on rehabilitation after treatment.
14 However, we do not know the impact on survival of either the prior or current follow-up regimen. A systematic review of the literature on the effects of follow-up with respect to the recurrence rate and survival was conducted in 2009; it included 17 retrospective studies from 1980 to 2007. The review could not present any overall benefit for survival from the detection of asymptomatic recurrences and encouraged further subgrouping of women treated for cervical cancer to identify individuals who may benefit particularly from surveillance. 1 To date, there are no randomized controlled trials for evaluating the follow-up of patients with treated cervical cancer. Here we present the first nationwide study aiming to investigate the recurrence rate, recurrence presentation, and mortality among women diagnosed with low-risk, early-stage cervical cancer. We intend to further stratify patients treated for earlystage cervical cancer in need of routine follow-up (traditional or intensified) as well as patients for whom followup may be of greater harm than benefit.
MATERIALS AND METHODS
During the study period, the posttreatment follow-up for cervical cancer in Denmark was planned for every 3, 6, or 12 months for 5 years, with a decrease in visits later during the follow-up period. The decrease in visits correlated well with the timing of recurrences of cervical cancer because the majority of all recurrences (62%-89%) are detected within the first 2 years after the initial treatment. 1, 15, 16 Data were extracted from 3 nationwide databases: From the DGCD, we extracted data on all patients diagnosed with cervical cancer in Denmark from January 2005 to September 2013 (International Classification of Diseases, Tenth Revision code C53.9). We excluded patients with an FIGO stage > IB1. From the DGCD, we collected the following clinical data on the patients: preliminary examinations, pathological information (DSI and LVSI), information on surgical treatment, and follow-up registration. To subgroup the women with DSI, we placed them into 1 of 3 groups according to the depth of invasion with respect to the total diameter of the cervix: < 1/3, > 1/3 and <2/3, or > 2/3.
We merged the DGCD findings with the NPR data to find patients registered with a new oncological treatment more than 3 months after the primary surgical treatment that was likely to be related to a recurrence: a new surgical intervention (conization or hysterectomy) or recurrent disease during palliative follow-up (according to coding). The identified patients were listed according to the FIGO stage, age, pathology, histology, LN status, DSI, and LVSI. All patients who had a recurrence or new treatment or were listed as dead in the NPR were crosschecked with their hospital charts and the Danish National Pathology Registry to ensure the correct Original Article classification. The hospital charts were also searched for information on the characteristics of the recurrence (symptomatic vs asymptomatic, location, and date). If any symptom mentioned by the patient led to further examination and henceforth the finding of a recurrence, the recurrence was classified as symptomatic, whereas asymptomatic recurrences were found clinically by a physician or, for example, radiologically as part of follow-up or as part of other workup. The recurrence rate and the mortality rate were calculated on the basis of all patients diagnosed with cervical cancer at FIGO stage IB1 or lower 
Statistics
Univariate and multivariate analyses were performed for patients with either SCC or AC. The time to recurrence and the time to death for patients with recurrence were analyzed with a Cox proportional hazards model. The time to death for patients with recurrence was calculated from the date of recurrence to death from all causes. The included explanatory variables were the tumor stage with the nodal status, histology, and age dichotomized at 50 years. For patients with recurrence, the method of diagnosis of recurrence, the site of recurrence, and pathological information were included as explanatory variables. Results are presented as hazard ratios with 95% confidence intervals (CIs), and the level of significance was P < .05. The assessment of model assumptions was performed with martingale residuals. Survival curves are based on Kaplan-Meier methods. Statistical calculations were performed with SAS (version 9.3; SAS Institute, Cary, North Carolina).
RESULTS
From the database, we identified 2914 patients with cervical cancer from January 2005 to September 2013. Of these, 1523 patients had cervical cancer at stage IB1 or lower. The distribution between the FIGO stages was as follows: 510 patients (33.5%) had stage 1A1 cervical cancer, 33 patients (2.2%) had stage 1A2 cervical cancer, and 980 patients (64.3%) had stage 1B1 cervical cancer. Table 1 shows descriptive data for the early-stage population. Among the 1523 patients, 80 recurrences and 97 deaths (6.4%) were detected. The 5-year recurrence rate was 6.4% (95% CI, 4.9%-7.9%) when we censored those women for whom we did not have 5 years of follow-up in our database at the time of data extraction (n 5 791) and 5.3% for the gathered population. The recurrences were dispersed according to the clinical data listed in Table 2 . We were unable to find data for recurrence diagnoses for 3 patients. Fifty-one of the 97 deaths were not related to cervical cancer. The remaining 46 deaths (3% of the entire population and 57.5% of the 80 recurrences) were distributed according to FIGO stages: 1 at stage 1A1 (the only patient with a positive LN at the initial diagnosis at stage 1A1) and 45 at stage 1B1.
The median time from recurrence to death was 27.3 months (95% CI, 16.5-49.1 months), and 64% (n 5 47) had their relapse within the first 2 years after the initial diagnosis.
Thirteen of the 23 patients with an asymptomatic recurrence had central pelvic recurrences, which were potentially detectable by a smear. However, only 4 of these patients' recurrences were found by a routine smear as part of the follow-up; the remaining 9 were determined by the biopsying of a suspicious lesion.
Among the patients at risk for recurrence in the population of 1415 women with either SCC or AC in the multivariate analysis, we found women at FIGO stage 1B1 to be at greater risk for recurrence, regardless of their LN status at diagnosis. We also found women who were older than 50 years or had lymphovascular LVSI at the initial diagnosis to have a significantly greater risk of recurrence, whereas histology (AC vs SCC), vascular LVSI, and DSI did not predict recurrence (Table 3) . Figure 2A ,B shows the overall survival of the entire population and the patients with recurrence. The effects of the clinical presentation at the initial diagnosis on survival after recurrence according to a univariate analysis are presented in Figure 3A -D. There was significantly inferior survival for patients with positive LNs, multiple sites of recurrence, and a symptomatic diagnosis of recurrence, whereas there was no significant difference in survival after recurrence when we looked at an age > 50 years or histology (AC vs SCC). For patients with a DSI < 1/3, the analysis showed statistically better survival in comparison with patients with a DSI > 2/3 ( Fig. 3A-D) . In a multivariate analysis, we found multiple sites of recurrence, a symptomatic diagnosis of recurrence, and LVSI to be significant parameters for death, whereas histology, LN status, age, and DSI were not (Table 4) .
DISCUSSION
In this study, we have presented the characteristics of women diagnosed with low-risk cervical cancer in Denmark between 2005 and 2013. Of the 1523 women with low-risk cervical cancer, 6.4% developed a recurrence, and 57.5% of these women died of their recurrence. We found that 67.5% of the recurrences were diagnosed symptomatically, and 28.8% had asymptomatic recurrences. The multivariate analysis showed that women older than 50 years, women with LVSI in their pathology report, and women diagnosed with stage 1B1 cervical cancer had a significantly greater risk of experiencing a recurrence. Furthermore, we found significantly inferior survival for women with a symptomatic recurrence or with recurrence at multiple sites in both univariate and multivariate analyses. Our study portrays a recurrence rate markedly lower than the rates reported in the majority of previous publications, which showed recurrence rates ranging from 8% to 26%. 1, 4, 16, 20 However, our findings are similar to the findings of Srisomboon et al, 21 who in a population of women with stage 1B1 cervical cancer found a recurrence rate of 5.8%. The incongruence in the published recurrence rates may be due to improvements in treatment over the past decades. The difference may also be explained by differences in the classification of early-stage cervical cancer. Some studies define early stage by surgical treatment, whereas others set their cutoff at FIGO stage 1B1 or 2A, regardless of high-risk factors, which could alter treatment from surgery to radiotherapy and chemotherapy; this makes comparisons between studies challenging. 1 Another reason for a lower recurrence rate in our population could be the insufficient registration of patients who are not undergoing treatment for their recurrence and patients with undiscovered recurrences. However, we estimate this group of women to be very small because women with untreated recurrences are assumed to die within a short time frame and would, therefore, be included in the NPR and hence in our examination of hospital charts. Our findings are supported by the 2009 systematic review by Elit et al 1 and strengthen the assumption that a majority of patients have a symptomatic recurrence. However, unlike Elit et al, we did find a difference in survival when we looked at symptomatic diagnoses of recurrence versus asymptomatic diagnoses in our multivariate model; this finding was perhaps enabled by our large cohort. In addition, the mean time from recurrence to death was longer among the asymptomatic patients than the symptomatic patients in our univariate analysis. These findings are supported by Mabuchi et al 12 and indicate the importance of a routine follow-up program for detecting asymptomatic recurrences and perhaps finding remaining recurrences before they become symptomatic. Conversely, the findings also suggest that the follow-up attended by the women during the study period did not have the desired effect because the majority of cases are found by the women themselves, and this appears to have a negative impact on survival. However, the role of possible lead-time and length-time biases with respect to the detection of recurrences cannot be disregarded. A lead-time bias is introduced when the early detection of recurrence falsely makes us believe that survival is longer, but the reality is that the patient lives with the knowledge of the recurrence for a longer period of time and can, in fact, die at the same time as another patient who has only recently been diagnosed with a recurrence. Likewise, a length-time bias occurs when fast-growing tumors, which are typically more aggressive and have a poorer prognosis, give rise to symptoms earlier than slow-growing tumors. By screening or follow-up, a disproportionate number of recurrences will be found in favor of asymptomatic recurrences, which in turn represent better survival because of tumor biology and not because of the early detection of the recurrence. A length-time bias tends to overestimate the value of screening/follow-up. 
Original Article
Our findings on LVSI as a prognostic factor for recurrence are supported by the existing literature and could enhance a practice in which these factors are taken into consideration when follow-up is being planned. 21, [24] [25] [26] [27] [28] The pathological subgrouping of LVSI into vascular, lymphovascular, or lymphatic space invasion that takes place in Denmark may serve as guidance to the clinician but should not determine guidelines because the majority of the studies do no subgrouping of LVSI. We also found significantly inferior survival among patients diagnosed with multiple sites of recurrence, and this corresponded to the findings by Sartori et al. 29 Finally, we demonstrated inferior survival for patients with positive LNs at the initial diagnosis, albeit only in our univariate model. However, this is consistent with the findings of Srisomboon et al. 21 Interestingly, only 4 recurrences were found by a regular smear over the 9-year period in which a smear was performed regularly as part of the follow-up. As is the case for corpus cancer, regular smears do not seem to have a place in the follow-up for detecting recurrences, nor do they seem to make sense from a cost-benefit point of view, with approximately 13,707 smears performed during our study period (9 smears per patient per follow-up 3 1523 patients). 30, 31 The method of retracting recurrence data from the NPR through an examination of new surgical or oncological treatments is supported by the hospital charts, but the study group acknowledges that an inverse method in which all charts from 2005 to 2013 were read might have been superior in terms of detecting more recurrences. Unfortunately, that was not within the scope or possibility of our resources. However, the unique NPR that we have in Denmark enabled us to find all deaths, all of which were cross-checked with hospital charts; this minimized the chance of a recurrence going unnoticed in our data.
With respect to the median time of 22 months from the initial diagnosis to recurrence, our study is limited by the short follow-up for women diagnosed in 2012-2013. A longer follow-up period for the women diagnosed in the latter period would have allowed more accurate listings of recurrence and death. A longer follow-up would also presumably result in a greater number of recurrences and thereby strengthen our conclusions.
To our knowledge, this is the first nationwide collection of data from women with early-stage cervical cancer. The data have been collected from 3 nationwide databases, and the results have been validated by chart review. The study presents the largest cohort of patients with early-stage cervical cancer to date. We found a low rate of recurrence in Denmark; however, we have with statistical significance managed to further characterize women with cervical cancer at a greater risk for recurrence and death, and this is what we initially set out to do.
In conclusion, our results identify a group of women at FIGO stage 1A1 in no need of specialized, hospitalbased follow-up after treatment for cervical cancer because there were only 8 recurrences and 1 death among 510 patients in this group over the past 9 years. Since our collection of data, these patients have, on account of a revision of the Danish follow-up program in 2015, no longer been seen routinely after treatment. Women with stage 1B1 cervical cancer have, on account of this revision, all been offered individualized follow-up, predominantly to cope with possible morbidity after treatment; the detection of recurrence is not the main focus because of the insufficient evidence to date for the effect of the early detection of recurrence on survival.
14 Likewise, no smear is performed regularly during this follow-up, which is highly patient-initiated. 7 However, our results point out that women with stage 1B1 cervical cancer would likely profit from regular clinical visits to detect asymptomatic recurrences because our results identify subgroups of women who are at greater risk for death and for whom intensified follow-up could potentially prolong life, although this latter conclusion remains uncertain. There are, therefore, strong implications for establishing evidence-based guidelines in this area, perhaps by further characterization of the group of women who could benefit from follow-up, and we, therefore, urge further prospective investigations in the future, possibly based on molecular risk markers.
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